AbbVie and OraSure Co-promote OraQuick® HCV Test in USA
OraSure Technologies has entered into a Master Program Services and Co-Promotion Agreement with AbbVie under which AbbVie and OraSure will co-promote the Company's OraQuick® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for hepatitis C (HCV). OraSure will be responsible for manufacturing and selling the product directly into all markets.
Under the agreement, OraSure has granted exclusive promotion rights to AbbVie for the OraQuick® HCV test in certain markets and will provide certain additional services in support of HCV testing. In exchange for the exclusive rights granted to AbbVie, OraSure will receive up to $75 million in exclusivity payments over the term of the agreement, which runs through December 31, 2019. In addition, upon achievement of certain performance-based milestones, OraSure will be eligible to receive additional payments annually over the life of the agreement. Further information regarding the agreement will be available in the Company's 8-K Report filed later today with the SEC.
The OraQuick® HCV test is the first and only FDA-approved and CLIA-waived point of care test for detection of HCV infection in at-risk individuals. The simple platform enables healthcare providers to deliver a diagnosis based on lab-accurate test results in 20 minutes, using fingerstick or venipuncture blood.
Tags: CLIA, Hepatitis C
Date Published: June 23, 2014
Source article link: OraSure Technologies, Inc. » company contact details
Automated Hepatitis Viral Load Testing Offered at LabCorp
Vela Achieves CE-IVD Marking for HCV Genotyping NGS Assay
Excellent Results from Multi-Centre Evaluation of DxN VERIS HIV-1 Assay
Case Study Shows How to Improve Viral Load Workflow
New Website for Beckman Coulter Diagnostics